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E-mail: llisowski@cmri.org.auAdeno-associated virus (AAV) vectors have become one of the
most widely used gene transfer tools in human gene therapy.
Considerable effort is currently being focused on AAV capsid
engineering strategies with the aim of developing novel vari-
ants with enhanced tropism for speciﬁc human cell types,
decreased human seroreactivity, and increased manufactur-
ability. Selection strategies based on directed evolution rely
on the generation of highly variable AAV capsid libraries using
methods such as DNA-family shufﬂing, a technique reliant on
stretches of high DNA sequence identity between input
parental capsid sequences. This identity dependence for reas-
sembly of shufﬂed capsids is inherently limiting and results
in decreased shufﬂing efﬁciency as the phylogenetic distance
between parental AAV capsids increases. To overcome this lim-
itation, we have developed a novel codon-optimization algo-
rithm that exploits evolutionarily deﬁned codon usage at
each amino acid residue in the parental sequences. This method
increases average sequence identity between capsids, while
enhancing the probability of retaining capsid functionality,
and facilitates incorporation of phylogenetically distant sero-
types into the DNA-shufﬂed libraries. This technology will
help accelerate the discovery of an increasingly powerful reper-
toire of AAV capsid variants for cell-type and disease-speciﬁc
applications.
INTRODUCTION
The recent approval of the gene and cell therapy products Glybera,1,2
Luxturna,3 and Strimvelis4 marks a pivotal point in the maturation of
the gene therapy ﬁeld. Signiﬁcantly, all of these products share a com-
mon technological underpinning: the use of recombinant viral vectors
to safely deliver therapeutic transgenes into target cells, an indication
of the importance of vector engineering for the future of gene therapy.
One of the most powerful gene transfer vectors used in current
research and clinical studies is based on recombinant adeno-associ-Molecular Therapy: Methods &
This is an open access article under the CC BY-NCated virus (rAAV).5 AAV is a single-stranded DNA virus ﬁrst em-
ployed as a gene transfer vector in 1984.6 Since AAV vectors entered
the clinic in 1994 there have beenmore than 160 phase I, II, and/or III
gene therapy trials utilizing rAAV, with the number initiated each
year increasing 3-fold since 2011 (http://www.abedia.com/wiley/
index.html). This accelerated adoption of rAAV technology reﬂects
therapeutic efﬁcacy in preclinical disease models and exciting early
success in human clinical trials, most notably in the liver, eye, and
CNS. A number of technical advances, such as discovery of vector
pseudo-serotyping, the development of scalable high-yield produc-
tion strategies,7–9 and the demonstration that rAAV can be used for
both gene addition and gene correction,10–12 have also contributed
to increased uptake of the AAV vector system. However, one of the
leading challenges that remains to be addressed, in order to achieve
the full therapeutic potential of rAAV, is limited efﬁciency in the
functional transduction of primary human cells. Given that the
tropism of AAV vectors is determined by the capsid,13 signiﬁcant
effort has been focused on AAV capsid engineering to develop novel
variants with enhanced human tropism.14,15
Multiple different approaches have been developed to facilitate iden-
tiﬁcation of novel AAV capsid variants with improved transduction
potential, ranging from searching for naturally occurring AAV vari-
ants in multiple different species, reconstructing ancestral vari-
ants,16–18 rational design based on custom modiﬁcation of AAV
properties by domain swapping,19 incorporation of tissue-speciﬁc
ligands on the vector surface,20 through to directed evolutionClinical Development Vol. 12 March 2019 ª 2018 The Authors. 71
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Methods & Clinical Developmenttechnologies.21 In contrast with rational design approaches, which
require extensive knowledge of the relationships between capsid
structure and function and AAV-target cell receptor interactions,
directed evolution technologies are based on better understood
AAV biology and aim to mimic the natural viral evolution process
in a controlled laboratory environment.22 In contrast with sequential
accumulation of mutations and modiﬁcations during natural evolu-
tion, directed evolution platforms rely on in vitro generation of large
pools of AAV variants, which can be used in in vitro or in vivo selec-
tion schemes in the presence of speciﬁc selection pressure(s). One of
the most commonly utilized molecular biology techniques to generate
highly complex AAV capsid libraries is based on DNA-family shuf-
ﬂing, ﬁrst adapted for use in the AAV system by Grimm et al.21
Shufﬂed AAV libraries have been successfully used by multiple
groups to identify novel AAV capsid variants with improved proper-
ties. Using an AAV library based on eight parental AAV capsids in an
in vitro selection system, Grimm et al.21 identiﬁed AAV-DJ, a variant
with superior transduction efﬁciency in multiple cell types in vitro.
Subsequently, similarly created libraries have been used to perform
transduction-based selection on primary human hepatocytes in a
xenograft mouse model of human liver, leading to the identiﬁcation
of AAV-LK0314 and more recently AAV-NP59,15 two novel human
hepatotropic variants. Because library production by DNA-family
shufﬂing involves enzymatic digestion of the parental AAV capsid se-
quences, followed by primerless PCR reassembly of DNA fragments
to create novel capsid gene (cap) variants, shufﬂing efﬁciency relies
on high degrees of sequence identity between parental serotypes at
the DNA level.23 This identity dependence makes parental variants
with higher sequence identity more efﬁcient shufﬂing substrates
and results in their overrepresentation in the ﬁnal library, whereas
DNA fragments from more distant capsid variants anneal less efﬁ-
ciently and are underrepresented (unpublished data). This identity-
based bias reduces library diversity and may affect the likelihood of
selecting optimal capsid variants.
In this study we describe an AAV shufﬂing strategy based on a novel
codon-optimization approach developed to increase the sequence
identity between parental capsid sequences while increasing the prob-
ability of retaining functionality. This strategy, designated localized
codon-optimization (LCO), was used to design novel lcoAAV
parental capsid variants with enhanced sequence identity for utiliza-
tion in AAV shufﬂing applications. Use of these new parental variants
facilitated more efﬁcient incorporation of evolutionarily distant, and
thus more sequence-divergent, variants, thereby conﬁrming the util-
ity and power of this new AAV engineering tool.
RESULTS
Wild-Type AAV Capsid Genes Are Suboptimal Substrates for
DNA Shuffling
The efﬁciency of parental cap gene shufﬂing during the generation of
AAV shufﬂed capsid libraries relies on stretches of sequence identity
between the input sequences at the nucleotide level.23,24 The level of
sequence identity of the capsid genes between 12 natural AAV isolates72 Molecular Therapy: Methods & Clinical Development Vol. 12 Marchused for library generation varied signiﬁcantly, with AAV1 and
AAV6 having the highest identity (97.1%) and AAV5 and AAV12
the lowest (55.1%). We hypothesized that such wide-ranging identi-
ties at the DNA level would directly inﬂuence the efﬁciency of
shufﬂing of the individual input sequences and bias the ﬁnal library,
leading to overrepresentation of sequences contributed by closely
related donor AAVs. To test this hypothesis and gain insight into
the sequence identity-dependent likelihood of input parental capsids
contributing sequences to individual clones within the highly com-
plex library, we performed an initial shufﬂing experiment using
capsid genes from three AAV serotypes belonging to Clade-A
(AAV6), Clade-B (AAV2), and a distant clonal isolate (AAV5). The
percent identity between these three capsid genes varied from
60.2% to 79.5%, with cap5 being the most distant variant, having
identity to cap2 and cap6 of 61.4% and 60.2%, respectively (Fig-
ure 1A). Analysis of individual clones (n = 36) from the ﬁnal shufﬂed
library, AAVLib256, revealed that overall library diversity (number of
unique clones within the pool) as well as clonal diversity (level of
sequence shufﬂing within individual clones) were low. Speciﬁcally,
the ﬁnal library contained a considerable percentage of clones
(25%, n = 9/36) that were 100% identical to parental AAV5 (data
not shown). In addition, the analysis conﬁrmed our hypothesis that
more distant AAV donors, such as AAV5, do not shufﬂe efﬁciently
with other variants and thus contribute poorly to shufﬂed clones
(clones 256_1 and 256_2 in Figure 1B). In addition, a large percentage
of the clones (36%) was >80% identical to AAV5 (clones 256_3 and
256_4 in Figure 1B), providing further evidence of inefﬁcient shuf-
ﬂing of parental variants sharing a lesser degree of sequence identity.
This almost certainly reﬂects the lower sequence identity between
fragments of AAV5 and other DNA fragments present during the
PCR reassembly step. Thus, fragments of AAV5 anneal to each other
more efﬁciently than to DNA fragments from other variants, leading
to preferential reassembly of the full-length or large fragments of the
AAV5 capsid gene. This observation suggests that libraries generated
using DNA-family shufﬂing that include more distant parental AAV
donors are more likely to contain a signiﬁcant proportion of full-
length wild-type (WT) variants. This is especially problematic when
attempting to create more diverse libraries with novel, often evolu-
tionary distant, variants such as Anc8016 or mAAV-EVE118 included
as parental donors. Our data indicate that these distant variants would
not readily contribute to individual clones and thus would not in-
crease complexity at the level of individual variants within the library,
but could adversely affect the quality of the ﬁnal library through reas-
sembly of full-length parental sequences.
Conventional Codon-Optimization Affects Function of Individual
Input Variants
To address the limitations of DNA shufﬂing efﬁciency using phyloge-
netically distant AAV serotypes, we attempted to increase the level of
sequence identity between individual parental variants using a conven-
tional codon optimization strategy (see Materials and Methods).
Because standard AAV packaging protocols utilize human HEK293T
cells, we decided to codon-optimize the cap genes of AAV2, AAV5,
and AAV6 (subsequently referred to as “hcoAAV”) based on human2019
Figure 1. Local Codon Optimization Increases DNA
Shuffling but Negatively Affects Packaging Function
(A) Percent identity between capsid genes of indicated
wild-type (WT) AAV serotypes. (B) Parental sequence
contribution analysis of sample clones isolated from
AAVLib256. Parental sequences are represented by red
(AAV2), green (AAV5), and blue (AAV6) lines. Size of ver-
tical bars represents probability that individual residue was
contributed by given parental vector. Black line represents
the most probable composition of individual shuffled
clones based on the longest sequence of identity to
parental variants in a 50 to 30 direction. (C) Percent identity
between variants codon-optimized using human codon-
usage table (hco). (D and E) rAAV yield comparison using
helper plasmids encoding wild-type cap genes (wtAAV2,
wtAAV5, wtAAV6, and wtAAV8) and corresponding
hcoAAVs in the absence (D) or presence (E) of serotype-
specific AAP provided in trans. vg = vector genomes.
Values in (D) and (E) are shown as mean ± SD (n = 3).
www.moleculartherapy.orgcodon-usage data (see Materials and Methods) (see Figure S3 for
sequence of hcoAAV cap genes). The rep gene major splice acceptor
site, start codons of VP2 and assembly-activating protein (AAP) were
not codon optimized and were maintained as in the WT counterparts.
This modiﬁcation increased the DNA sequence identity between indi-
vidual variants, with hcoAAV5 being 73.4% identical to hcoAAV2 and
73.3% to hcoAAV6 (Figure 1C). Because the function of variants
selected from a library is directly linked to the functionality of the input
variants, we performed functional analysis of hcoAAVs. To test the
packaging efﬁciency, we used the three hcoAAV cap genes to generate
pAAV packaging constructs containing the AAV2 rep gene. The resul-
tant constructs, designated pAAV-hcoAAV2, pAAV-hcoAAV5, and
pAAV-hcoAAV6, were used to package the AAV cassette expressing
GFP under the control of a liver-speciﬁc promoter (LSP) (AAV-LSP-
GFP) in parallel single-dish productions (n = 3) using theWT counter-
parts (pAAV2, pAAV5, and pAAV6) as controls. Because codon-opti-
mization of the ﬁrst open reading frame (ORF) affected sequences of
individual aap25 genes encoded on the second reading frame (data
not shown), it was not surprising that sequence optimization had a dra-
matic negative effect on all individual variants leading to signiﬁcantly
lower vector yields (Figure 1D). Because AAP26 is known to play an
important role as an essential accessory protein for efﬁcient assembly
of functional AAV capsids,27,28 we examined whether packaging of
the hcoAAVs could be rescued by providing serotype-speciﬁc AAPs
in trans during vector packaging. Interestingly, AAP complementation
failed to substantially restore packaging efﬁciency (Figure 1E), indi-Molecular Therapy: Methods &cating that codon-optimization affected pro-
cesses and elements other than those related to
AAP activity. To test whether the observed
decrease inpackaging efﬁciency after codon-opti-
mization affects other AAVs, we generated and
evaluated hcoAAV8 using the same approach
with essentially the same outcome (Figures 1D
and 1E). Collectively these data support theconclusion that conventional codon-optimization of cap gene se-
quences is an inadequate methodology for increasing nucleotide
identity between input AAV sequences for DNA-family shufﬂing
applications.
Novel Codon-Optimization Method Increases Capsid Sequence
Identity while Retaining Function
The dramatic loss of vector packaging efﬁciency after conventional
codon-optimization (hcoAAVs) suggests that AAV capsid gene se-
quences, in addition to encoding structural capsid proteins and
AAP, may contain other currently unknown elements important
for cap gene function and AAV assembly. Accordingly, an alternative
method of codon optimization was developed and evaluated for the
ability to increase identity between individual AAV cap genes while
maintaining the functionality of individual variants. We hypothesized
that one way to preserve functional elements of the cap genes, while
increasing identity between input genes, would be to only utilize co-
dons used by input variants at each individual optimized position. To
achieve this, we developed a novel codon-optimization method for
improving the level of identity between serotypes while potentially
maintaining capsid functionality. This localized codon-optimization
(LCO) strategy increases identity between parental sequences by
performing localized optimization at each codon independently of
the rest of the gene sequence. Speciﬁcally, by generating a codon usage
frequency table for each of the amino acid positions and then
applying this local codon usage table to optimize individualClinical Development Vol. 12 March 2019 73
Figure 2. Functional Evaluation of AAVs Modified
Using Localized Codon-Optimization Algorithm
(A) Percent identity at theDNA level between sequencesof
optimized AAV2, AAV5, and AAV6 capsid genes
(lcoAAV2, lcoAAV5, and lcoAAV6, respectively). (B) DNA
identity tree between cap genes from wtAAVs (wtAAV2,
wtAAV5, and wtAAV6, in black) and LCO cap genes
(lcoAAV2, lcoAAV5, and lcoAAV6, in purple). The numbers
indicate the frequency of nucleotide substitutions per site.
(C) rAAV yield comparison from three independent crude
productions using helper plasmids encoding optimized
capsids (lcoAAV2, lcoAAV5, and lcoAAV6) (gray bars:
LCO). Packaging constructs encoding wild-type cap
genes (wtAAV2, wtAAV5, wtAAV6) served as controls
(black bars: WT). (D) Functional comparison between re-
combinant AAV2, AAV5, and AAV6 (WT: black bars) and
lcoAAV2, lcoAAV5, and lcoAAV6 (LCO: gray bars). HuH7
cells were transduced at anMOI = 5.0 103 for AAV2 and
AAV6 variants and at an MOI = 5.0  104 for AAV5 vari-
ants, with vectors encoding EGFP under the control of a
liver-specific promoter (LSP). FACS analysis of EGFP was
performed 72 hr after transduction. Values in (C) and (D)
are shown as mean ± SD (n = 3).
Molecular Therapy: Methods & Clinical Developmentsequences, the LCO algorithm minimizes the arbitrary changes that
conventional codon optimization approaches introduce to the
sequence (see Materials and Methods and Figure S1 for details).
To test the LCO algorithm, we performed localized codon-optimiza-
tion of capsid genes from AAV2, AAV5, and AAV6 (subsequently
referred to as lcoAAV2, lcoAAV5, and lcoAAV6). This modiﬁcation
increased the average identity between the three parental AAV caps
by 10.03% when compared with wtAAV cap sequences (Figures 1A
and 2A) and decreased the frequency of nucleotide substitutions
per site (Figure 2B). In silico analysis of lcoAAVs conﬁrmed that
the essential and therefore homologous regions of the AAV genomes,
such as the splice acceptor site (residue 2,228 in the wtAAV2 genome,
GenBank: NC_001401.2), the VP2 and VP3 start codons (residues
2,614 and 2,809 in the wtAAV2 genome, GenBank: NC_001401.2),
and the AAP start codon (CTG, residue 2,729 in the wtAAV2
genome, GenBank: NC_001401.2) were preserved. An important
aspect was to conﬁrm whether optimizing the VP proteins, encoded
in the ﬁrst ORF, would have a negative effect on the AAP ORF en-
coded in the second reading frame and thus affect capsid function.
In order to test functionality of the lcoAAVs, AAV packaging plas-
mids encoding optimized capsid sequences of AAV2, AAV5, and
AAV6 were generated and used to package the AAV-LSP-GFP
cassette in independent transfections (n = 3 per capsid), using the cor-
responding WT packaging constructs as controls. In marked contrast
with the results obtained with hcoAAVs (Figure 1D), no substantial
effect on lcoAAV vector yield was observed when compared with
the wtAAV counterparts (Figure 2C). Western blot analysis revealed
that, in contrast with hcoAAV2, steady-state levels of VP proteins
from lcoAAV2 were indistinguishable from those detected for
wtAAV2 control (Figure S5). Addition of AAP in trans had no effect
on vector yield (data not shown), indicating that each of the lcoAAVs74 Molecular Therapy: Methods & Clinical Development Vol. 12 Marchencoded functional AAP. Detailed analysis of lcoAAV2 revealed that
codon optimization introduced an early stop codon in the AAP2 ORF
leading to loss of two amino acids at the C terminus. Of the remaining
202 amino acids, 165 (81.68%) were fully conserved, 7 were conserva-
tive substitutions (3.47%), 5 semi-conservative (2.48%), and the
remainder (25 amino acids [aa], 12.37%) non-conservative. Impor-
tantly, none of the non-conservative mutations occurred on AAP’s
hydrophobic region (HR) nor on its conserved core (CC), the two
essential domains recently described to mediate AAP-VP interactions
in the context of AAV1.29 In fact, similar analysis on AAP1 revealed
that the two essential regions are also conserved, thus providing
further support to the hypothesis that local codon optimization pre-
serves AAP functionality (Figure S4).
Sequence analysis also revealed that codon-optimization introduced a
premature STOP codon in the X gene in lcoAAV2. Protein X has been
implicated in AAV2 DNA replication, and mutations inhibiting X
gene expression have been shown to cause a decrease in AAV repli-
cation and yield.30 However, our data show that truncation of the
C terminus of protein X in lcoAAV2 had no effect on vector yield
(Figure 2C), indicating that activity of protein X has not been affected
or that protein X is dispensable. Most importantly, transduction
studies performed using HuH7 cells showed that the transduction ef-
ﬁciency of lcoAAVs was similar to the wtAAV counterparts (Fig-
ure 2D), indicating that codon optimization using the LCO algorithm
preserved vector yield and function.
LocalizedCodon-Optimization of Parental Sequences Increases
Identity and Improves DNA Shuffling of Distant Serotypes
To evaluate the effect of sequence optimization on the efﬁciency of
capsid shufﬂing, we used codon-optimized capsid genes (lcoAAV2,
lcoAAV5, and lcoAAV6) as input sequences to create a shufﬂed li-
brary (AAVLiblco256). Random clones (n = 42) from the ﬁnal library2019
Figure 3. AAV Shuffled Library Based on lcoAAV2,
lcoAAV5, and lcoAAV6
(A) Sequence analysis of representative clones from
AAVLiblco256 showing increased shuffling efficiency at the
DNA level. (B) Number of individual parental segments
contributing to clones from shuffled AAV library based on
capsids from wtAAV2, wtAAV5, and wtAAV6 (AAVLib256)
(4.37 ± 0.53, mean ± SEM) and library generated using
localized codon-optimization (LCO) algorithm optimized
caps (AAVLiblco256) (17.31 ± 0.57, mean ± SEM). (C) Size
distribution and mean (red line) size of parental fragments
contributing to clones (n = 145) from AAVLib256 (407.2 ±
44.91, mean ± SEM) and AAVLiblco256 (129.5 ± 11.6,
mean ± SEM). (D) Sequence composition of clone HuH-
R6C12 isolated from AAVLiblco256 library during selection
screen on HuH7 cells. (E) Functional analysis of HuH-
R6C12 clone. HuH7 cells were transduced with iodixanol
preparations of rAAV-HuH-R6C12, control wild-type (WT)
vectors (rAAV2, rAAV5, and rAAV6), and lcoAAV vectors
(lcoAAV2, lcoAAV5, and lcoAAV6) at MOIs indicated.
FACS analysis of EGFP was performed 72 hr after
transduction. Values are shown as mean ± SD (n = 3).
****p < 0.0001.
www.moleculartherapy.orgwere fully sequenced to evaluate the presence of reassembled parental
capsids and level of capsid shufﬂing. Detailed analysis of the
sequenced clones revealed a marked increase in complexity at the
level of individual variants within the library (Figure 3A). In compar-
ison with the library generated using capsid sequences from wtAAV2,
wtAAV5, and wtAAV6, which on average contained 4.37 ± 2.68
individual parental sequences per clone, clones in the new library
contained on average 17.3 ± 3.70 individual fragments from parental
donors (Figure 3B). Furthermore, the average size of each donor
sequence segment decreased from 407 bp in AAVLib256 to 120 bp
in AAVLiblco256 (Figure 3C), consistent with improved shufﬂing efﬁ-
ciency as a direct consequence of increased identity at the DNA level
between input sequences. Furthermore, while all of the sequenced
clones from the AAVLiblco256 library contained shufﬂed sequences
from lcoAAV5, the percentage contribution ranged from 6.5% to
68%, and only 11.6% were >50% identical to AAV5 (data not shown),
indicating that the use of lcoAAVs in shufﬂing protocol lowered the
frequency of full AAV5 capsid reassembly.
To test functionality, we cloned the novel highly shufﬂed library into a
replication-competent recipient construct containing inverted termi-
nal repeats (ITRs) and the rep gene (ITR-Rep-Caplibrary-ITR). The li-
brary was efﬁciently packaged using a standard transfection protocol
and yielded 2 102 vector particles per packaging cell (2 1010 totalMolecular Therapy: Methods &particles per ﬁve 15-cm dishes). The library was
used to perform six rounds of selection onHuH7
cells in the presence of wtAd5 virus, to facilitate
library replication. Starting from round 4, at each
round n= 20 cloneswere sequenced to track pro-
gression of the selection process. After round 6
of selection, a dominant AAV variant, clone 12(designated HuH-R6C12), represented 40% of the analyzed pool of
clones examined. Sequence analysis of AAV-HuH-R6C12 revealed
that this novel variant was composed of sequences contributed by
parental lcoAAV2, lcoAAV5, and lcoAAV6 (Figure 3D), providing
a direct conﬁrmation that lcoAAVs allow generation of shufﬂed clones
that would be difﬁcult or impossible to obtain using standard, unopti-
mized, AAV capsid sequences.
In order to evaluate the transduction potential of the selected HuH-
R6C12 clone on HuH7 cells, the HuH-R6C12 cap gene was recovered
using PCR, cloned into a standard AAV-helper construct containing
the rep2 gene, and used to package theAAV-LSP-GFP construct. Pack-
aging constructs expressing WT and lcoAAVs (pAAV2, pAAV5,
pAAV6 and pAAV-lcoAAV2, pAAV-lcoAAV5, pAAV-lcoAAV6)
were used in parallel to package the same AAV cassette and served as
controls. The AAV-HuH-R6C12 vector functionally transduced
48.4% of HuH7 cells at MOI 500 (Figure 3E), validating the shufﬂing
of lcoAAVs as a new addition to the AAV engineering toolbox.
lcoAAVs Enable Generation of Highly Diverse Libraries from
Multiple Phylogenetically Distant Capsids
We next sought to validate the new codon optimization strategy by
generating shufﬂed libraries using a larger number of input AAV
cap sequences. To achieve this, we ﬁrst used the LCO algorithm toClinical Development Vol. 12 March 2019 75
Figure 4. Functional Evaluation of AAV1–12
Optimized Using Localized Codon Optimization
Method
(A) Evaluation of lcoAAVs cap genes based on packaging
efficiency. rAAV vectors produced using AAV-helper
plasmids encoding corresponding wild-type cap genes
were used as controls and were assigned a value of
100%. For clarity and convenience, we show again data
for AAV2, AAV5, and AAV6 from Figure 2C. (B) Evaluation
of the effect of AAP12 on packaging efficiency of
lcoAAV12. (C) Functional assessment of rAAV vectors
produced using lcoAAV and wtAAV cap genes for their
ability to functionally transduce HuH7 cells. All values are
shown as mean ± SD (n = 3).
Molecular Therapy: Methods & Clinical Developmentoptimize sequences of 12 parental wtAAVs (AAV1–12). To perform
functional analysis of lcoAAV1–12, each lcoAAV capsid sequence
(excluding the previously cloned lcoAAV2, lcoAAV5, and locAAV6)
was used to generate the corresponding pAAV-lcoAAV packaging
construct, which was subsequently used to test the ability to assemble
into AAV particles. Packaging tests, performed in parallel with con-
structs encoding wtAAV cap sequences in independent packaging
reactions (n = 3), revealed that the majority of optimized capsids re-
tained packaging ability (Figure 4A). From the AAV panel tested,
only lcoAAV12 showed a substantial decrease to 5.06% of wtAAV12
titer, which was partially rescued to 29.08% of wtAAV12 by providing
AAP12 in trans (Figure 4B). Functional analysis on HuH7 cells (Fig-
ure 4C) revealed that codon optimization did not affect function of
individual vectors when compared with wtAAV controls.
Next, lcoAAV1–12 were used to perform AAV capsid shufﬂing and
library generation. In order to test the ability of capsid shufﬂing based
on lcoAAV parental inputs to enhance shufﬂing of variants with
lower identity at the DNA sequence level, we also included two novel,
phylogenetically distant, contemporary AAV variants isolated from
contemporary Australian marsupials (mAAV1) and an ultra-ancient
AAV-derived endogenous viral element found within the genome of
multiple marsupial species (mAAV-EVE1) (Figure 5A). Because the
mAAV-EVE1 and mAAV1 variants had not been vectorized using
the canonical AAV2 genome (Rep/ITR) (data not shown), the LCO
algorithm’s built-in option was utilized to perform localized codon-
optimization of mAAV-EVE1 and mAAV1 using sequence input
from AAV1–12 only, without using mAAV-EVE1 and mAAV1 as76 Molecular Therapy: Methods & Clinical Development Vol. 12 March 2019input (Figure S6). As expected, localized
codon-optimization increased identity between
individual variants by up to 11.5% when
compared with WT sequences (Figure 5B),
with the identity range between variants
increasing from 55%–75% to 75%–85%
(Figure 5C).
Having optimized all 14 input sequences
(AAV1–12, mAAV1, and mAAV-EVE1), we
next performed DNA shufﬂing and generatedlibraries composed of lcoAAV1–12 only as well as lcoAAV1–12
including mAAV-EVE1 and mAAV1 (referred to as E and M in
library names). In parallel, control libraries were generated
using the same combination of parental unoptimized sequences.
Thus, four shufﬂed capsid libraries were generated and
designated AAVLiblco1–12 and control AAVLib1-12, as well as
AAVLiblco1–12+EM and control AAVLib1–12+EM.
Sequence analysis of individual clones from each of the libraries
(n = 40 per library) revealed that while the average number of
individual sequence segments contributing to the fully reassembled
capsid genes did not change considerably, the number of individual
parental variants contributing to shufﬂed clones did increase for li-
braries based on lcoAAVs (Table 1). We also observed a moderate
decrease in the average length of donor sequence segments for library
AAVLiblco1–12+EM when compared with control AAVLib1–12+EM
library (Table 1).
The effects of using lcoAAV in capsid shufﬂing protocols became
clear when the shufﬂing index (SI), expressed as percentage of indi-
vidual clones containing at least one fragment (>15 bp) from a given
parental donor, was calculated (Figures 5D and 5E). Speciﬁcally, the
percentage of clones containing sequences from each of the individual
parental donors in AAVLib1-12 and AAVLib1-12+EM paralleled the
level of identity between individual donor sequences (Figure 5C),
with the less identical variants (AAV5, AAV11, AAV12, mAAV1,
and mAAV-EVE1) contributing to fewer shufﬂed clones. In striking
contrast, the shufﬂing was more uniform between individual variants
Figure 5. Parental Capsid Phylogeny, LCO-Based
Enhancement of Sequence Identity, and Increased
Shuffling Efficiency
(A) Phylogenetic relationship among the 14 AAV variants
used in the study. (B) Relative increase in percent identity
between wtAAV cap genes and cap genes optimized
using the LCO algorithm. Values = %homologyLCO  %
homologyWT. (C) Percent identity between individual
wtAAV cap genes and lcoAAV cap genes. (D and E)
Changes in shuffling index between plasmid libraries (D)
and packaged AAV libraries (E) generated using wtAAV
cap and lcoAAV cap, with green color indicating higher
and red indicating lower shuffling index. n = 40 clones per
library were used in the analysis.
www.moleculartherapy.org(higher SI) for libraries based on lcoAAVs (AAVLiblco1–12 and
AAVLiblco1–12+EM) (Figures 5D and 5E), and again paralleled the
identity between individual lcoAAVs (Figure 5C). Importantly, the
more efﬁcient shufﬂing was observed at the DNA level (Figure 5D)
and in the ﬁnal packaged AAV library (Figure 5E), conﬁrming that
cap variants containing sequences frommore phylogenetically distant
parental donors are functional and can assemble into AAV particles.
These data clearly demonstrate that the novel system reported herein
allows the generation of libraries containing distantly related family
members and validates sequences optimized using LCO as a powerful
tool for AAV shufﬂing applications.
DISCUSSION
There is immense and growing excitement around AAV-based gene
therapy in both the academic and commercial sectors. Leading dis-
ease indications based on evidence of therapeutic efﬁcacy involve tar-
geting the eye,31–33 CNS (reviewed in Hocquemiller et al.34), and liver
(reviewed in Baruteau et al.35 and Nathwani et al.36), with diseases in
multiple other target tissues at various stages of preclinical and clin-
ical development.37–42 To date, most AAV-based vectors used in hu-
man studies have been naturally occurring variants, such as AAV2,
AAV5, AAV8, AAV9, and AAVrh10. Accumulating preclinical and
clinical data indicate that many of the currently utilized AAV sero-
types are less efﬁcient at functionally transducing primary humanMolecular Therapy: Methods &cells than would be predicted from preclinical
data obtained in in vitro and in vivo models.
For example, based on analysis of the results
of a hemophilia B clinical trial, where 2  1012
vg/kg of self-complementary (sc)AAV2/8 was
used to deliver a codon-optimized human factor
IX (hFIX) cDNA,36 one can estimate that only a
few percent of human hepatocytes were
functionally transduced and contributed to
AAV-mediated hFIX transgene expression,
with resultant peak FIX activity of 10%–12%
of physiological levels. The same vector
(scAAV2/8-LP1-hFIXco) tested at the same
dose in non-human primates (NHP) led to
transduction of 96%–99% hepatocytes with anaverage of 88–142 transgene copies per cell and peak hFIX levels be-
tween 399% ± 58% and 580% ± 34% of normal,43 while a similar dose
of 1.2  1010 vg/mouse of ssAAV8 vector transduces the majority of
mouse hepatocytes with average vector copy number of 1 per
diploid genome.44 This highlights two critically important technolog-
ical limitations that need to be addressed in order for AAV vectors to
reach their full clinical potential: ﬁrst, the failure of commonly used
preclinical models to reliably predict human therapeutic utility; and
second, the inadequate transduction efﬁciency of contemporary
AAV capsid variants to treat many disease phenotypes potentially
amenable to gene therapy in important target tissues, such as the hu-
man liver. AAV directed evolution has been successfully used to
generate novel AAV variants with improved transduction of target
cells/tissues. During this process, selection pressure is applied to an
AAV library containing a large number of random variants of the
capsid gene, each with unique sequence composition, and thus poten-
tially unique tropism. One of the commonly utilized methods to
generate AAV cap libraries is through DNA-family shufﬂing, a
technique reliant on random fragmentation of capsid genes and
PCR-based reassembly, facilitated by stretches of high sequence iden-
tity between different input capsid variants. Of note, the ﬁrst synthetic
AAV variant, AAV-LK03,14 selected using a directed evolution strat-
egy for the ability to transduce primary human hepatocytes, has
recently reached the clinic in the context of a gene therapy trial usingClinical Development Vol. 12 March 2019 77
Table 1. Quantitative Comparison of Shuffling Efficiency between AAV Libraries Generated Using Standard and lcoAAV Inputs




17.77 ± 4.77 16.97 ± 3.09 14.57 ± 4.71 16.77 ± 3.21
Average length of
donor segments (bp)
118.9 122.12 140.8 126
Number of parental
variants contributing




19.66 ± 3.87 15.91 ± 3.78 16.50 ± 3.84 17.00 ± 4.93
Average length of
donor segments (bp)
130.32 138.43 124.61 135.44
Number of parental
variants contributing
7.17 ± 1.52 9.01 ± 1.38 6.41 ± 1.93 9.30 ± 1.87
Molecular Therapy: Methods & Clinical DevelopmentAAV vector encoding human factor VIII (hFVIII) for hemophilia
A.45 Based on the level of hFVIII activity, it is reasonable to conclude
that the transduction efﬁciency achieved with the AAV-LK03 capsid
is almost certainly higher than with any other vector tested in a clin-
ical setting at the same dose, and supports preclinical predictions
made using the FRG (Fah//Rag2//Il2rg/) human liver xeno-
graft mouse model.10
Despite the power of directed evolution to select highly functional
novel AAV variants, the main limitation of this approach is the efﬁ-
ciency with which parental capsid sequences can be shufﬂed, a critical
step in library preparation that relies on stretches of DNA sequence
identity between individual input capsid sequences. Because individ-
ual AAV serotypes differ to various degrees from one another, this
has the potential to limit library complexity and cause unintentional
bias in library composition. The predicted outcome of such bias would
be underrepresentation of variants with lower sequence identity and
overrepresentation of sequences from parental variants with higher
sequence identity. Our results obtainedwith anAAV library generated
by shufﬂing cap 2, 5, and 6 (AAVLib256) validate these concerns. Se-
quences fromAAV5,which shares the lowest level of sequence identity
among these capsids, proved more likely to recombine with other
AAV5-derived fragments, leading to a high percentage of clones con-
taining over 80% AAV5 genome and 25% of clones that were 100%
AAV5. The likely explanation is that as a consequence of lower
sequence identity with AAV2- and AAV6-derived DNA fragments
present during the PCR reassembly step, AAV5-derived fragments an-
nealed to each other more efﬁciently than to DNA fragments from
AAV2 and AAV6, leading to preferential reassembly of the AAV5
cap gene or substantial proportions thereof. This effect can be reduced
by introducing additional sequences into the reaction mixture, as in
the case of AAVLib1-12 or AAVLib1–12+EM, generated from 12 and
14 parental donors, respectively, in which full-length AAV5 cap was
not detected. This is attributable to the fact that in a library based
on a larger number of parental donors, the chance of individual
DNA fragments from the same parental donor interacting with one78 Molecular Therapy: Methods & Clinical Development Vol. 12 Marchanother is reduced, decreasing the probability of full-length capsid re-
assembly. Furthermore, the distribution of sequence identities be-
tween individual fragments within the PCRmixture is more normally
distributed in the context of larger libraries, increasing the probability
that fragments with lower degrees of identity will encounter another
fragment with sufﬁciently high identity to allow annealing.
In order to minimize this bias introduced during the DNA shufﬂing
step by variants with lower sequence identities, we initially performed
conventional codon optimization to increase pairwise identities be-
tween individual variants. Utilization of a single codon for each
amino acid throughout the sequence, while having the most signiﬁ-
cant positive effect on the level of sequence identity, proved to have
a negative effect on expression of capsid VP proteins (hcoAAV2 in
Figure S5), leading to a dramatic decrease in vector titers. More inter-
esting, however, was the fact that addition of corresponding AAPs in
trans did not increase the total level of VP protein detected and did
not rescue vector packaging. This result implies that AAV capsid
genes encode additional currently unknown factors, or motifs, that
serve important functions during cap expression and/or capsid as-
sembly. Notably, the novel enhancer-promoter element recently iden-
tiﬁed in the 30 UTR of AAV246 further supports the possibility that in
order to fully utilize the limited genome size, AAV could use all six
DNA reading frames and thus contain additional coding or func-
tional regions that remain to be identiﬁed. Should additional data
become available in support of this hypothesis, the known level of
genomic complexity of this “simple” virus would increase signiﬁ-
cantly and many of the commonly accepted assumptions related to
AAV biology and vectorology would need to be reevaluated. Alterna-
tive sophisticated algorithms and methods to codon-optimize DNA
sequences for protein engineering have been described;23,24,47,48 how-
ever, to the best of our knowledge, they currently remain untested in
the context of large structural viral proteins.
By exploiting individual triplet codons utilized by parental input var-
iants, the new LCO algorithm presented here allows identity between2019
www.moleculartherapy.orgindividual input AAV variants to be increased (Figure 5B) while mini-
mizing the risk of loss of vector function (Figure 4; Figure S5). The
increased identity between individual input parental AAV cap genes
led to more efﬁcient shufﬂing as measured by decreased average size
and increased number of individual fragments contributing to fully
reassembled cap variants within shufﬂed AAVLiblco256 (Figures 3B
and 3C). As expected, this effect was less dramatic in the context of
libraries generated using a larger number of input cap genes
(AAV1–12 + mAAV-EVE1 and mAAV1) (Table 1), due to the fact
that many of the variants were over 70% identical to one another
even before the codon optimization step, allowing efﬁcient shufﬂing
between such variants. Importantly, despite the fact that in more
complex libraries the average size and number of individual parental
fragments contributing to reassembled cap variants did not change
substantially between LCO and WT libraries (Table 1), the number
of contributing parental variants per clone (Table 1) and the percent-
age of clones containing sequences from each parental donor (Fig-
ure 5E) increased when lcoAAVs were used as input sequences. These
results indicate that the LCO algorithm facilitates more efﬁcient shuf-
ﬂing and increases the frequency of individual clones containing frag-
ments from more distant variants.
The shufﬂing of more distantly related sequence fragments, as facili-
tated by LCO, could potentially increase the proportion of individual
variants within an AAV capsid library that are incapable of efﬁciently
packaging an ITR-ﬂanked DNA cargo, or are otherwise functionally
impaired owing to structural incompatibility of capsid domains dur-
ing assembly or packaging. Furthermore, diverse capsid contributions,
even among clones that do package efﬁciently, will not necessarily
translate into functional superiority of selected variants. Variants con-
taining capsid gene elements derived from diverse parental capsids
could also fail to successfully cross-complement the ITRs and Rep
derived fromAAV2, whichwould further complicate themanufacture
of vectors utilizing such capsids. Accepting this uncertainty, the
important positive consequence of increased library diversity is the
otherwise unavailable prospect of identifying novel functional variants
that would not exist in a less phylogenetically diverse library.
Out of the 12 AAV serotypes tested (Figure 4A), only AAV12 showed
a decrease in vector packaging efﬁciency when the capsid sequence
was optimized using the LCO algorithm. Expression of AAP12 in
trans partially rescued vector packaging, providing further evidence
supporting the hypothesis that AAP may not be the only accessory
protein involved in AAV packaging. Interestingly, a number of
AAV serotypes (AAV1, AAV3, AAV5, and AAV6) appear to be
more efﬁcient at packaging following LCO modiﬁcation (Figure 4A).
Although this may be related to the availability of speciﬁc tRNAs in
HEK293T cells, it might also indicate that codon optimization on
the ﬁrst ORF as part of LCO affected cap gene functional elements
and/or led to generation of more functional variants of accessory pro-
teins involved in AAV packaging or replication.
In summary, AAV capsid shufﬂing based on lcoAAVs can be used to
enhance currently utilized AAV shufﬂing at the DNA level, therebyMoleculproviding a powerful addition to the AAV engineering toolbox. It is
important to point out that the AAV cap shufﬂing based on lcoAAVs
is a complementary method, not a replacement, to currently utilized
shufﬂing methods. The authors do not claim that lcoAAV libraries
are superior to libraries based on wtAAV or will necessarily lead to
identiﬁcation of more functional variants. The properties of selected
variants depend on the library and selection model, and to this end,
shufﬂing based on lcoAAVs offers an efﬁcient way to generate li-
braries composed of highly shufﬂed clones, which otherwise have
an extremely low probability of being present in libraries based on
wtAAVs. Furthermore, based on the functional data obtained with
lcoAAV capsids, the localized codon-optimization algorithm could
be applied more generically for DNA shufﬂing of other genes to in-
crease the identity of input parental sequences with reduced likeli-
hood of impairing function. Importantly, this new technology can
enhance other techniques based on homologous recombination,
such as staggered extension process (StEP), random chimeragenesis
on transient templates (RACHITT), and nucleotide exchange and
excision technology (NExT), making localized codon-optimization
a powerful new tool with potential applicability and signiﬁcant impact
on the broader ﬁeld of bioengineering.
MATERIALS AND METHODS
Standard Codon Optimization
Conventional human codon optimization was performed using
Geneious (version 9.1.5) (https://www.geneious.com/).49 The nucleo-
tide sequence identity between individual parental variants was
increased using the Codon Adaptation Index (CAI) of a gene
sequence as the geometric mean of the relative adaptiveness of the co-
dons in the sequence, as deﬁned in Sharp and Li.50 Speciﬁcally, the
human codon frequency table was used to identify the codon most
commonly used for each of the individual amino acids. Subsequently,
the cap genes were reverse translated, applying the single most
commonly used codon for each of the amino acids, so that the ﬁnal
codon-optimized variants were represented by the most likely non-
degenerate coding sequence, and thus have the highest CAI.
Localized Codon-Optimization Algorithm
The LCO algorithm was written in Java as a native Geneious (version
9.1.5) (https://www.geneious.com/)49 plugin (the plugin and in-
structions are available for free download at https://github.com/
CMRI-TVG/AAVcodons). The resulting enhanced-identity se-
quences are exportable to a FASTA format. The algorithm performs
a speciﬁc multiple sequence alignment (MSA) on the target sequences
using ClustalW2.51 In order to preserve the amino acid sequence of
each variant, the algorithm uses translationMSAwhere nucleotide se-
quences are translated to amino acid sequences while saving posi-
tional references. The resulting amino acid sequences are then aligned
and re-converted back to nucleotide sequences by using the positional
references. Using the nucleotide MSA as input, the algorithm iden-
tiﬁes individual codons, translates them, and identiﬁes positions
with 100% amino acid conservation. For those positions, the algo-
rithm creates a local codon-usage table and selects the most common
codon in all the variants in the alignment. In the case where twoar Therapy: Methods & Clinical Development Vol. 12 March 2019 79
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amino acid, the position is assigned to the codon of the ﬁrst capsid
used in the alignment, in our case, AAV1. In regions with indels,
the algorithm ignores the sequences that have a gap and performs
local codon optimization for all other sequences following the same
method (Figure S1). To increase ﬂexibility, the algorithm allows selec-
tion of input variant(s) that will not be included in the calculation of
the most common codon, but will undergo codon optimization. This
feature is important when including unveriﬁed or incomplete
parental variant sequences. Furthermore, this feature allows users
to perform codon optimization of novel parental sequences at a later
point, without affecting previously optimized variants.
Sequence Contribution Analysis and Graphical Representation
To allow convenient contribution analysis of shufﬂed capsids, a
Sequence Origin Depiction (SOD) plugin was created for Geneious
(https://www.geneious.com/)49 (the plugin and instructions are
available for free download at https://github.com/CMRI-TVG/
AAVcodons). In contrast to a commonly used Xover tool (http://
qpmf.rx.umaryland.edu/xover.html),52 the SOD allows the user to
zoom in on the output sequence to perform detailed analysis at the
nucleotide level. The tool also displays the crossover number, number
of point mutations, Levenshtein distances to all parental sequences,
effective mutation, as well as mean, minimum, and maximum size
of contributing fragments. For convenience, the SOD graphical
output can be exported in a number of ﬁle formats. Speciﬁcally, the
graphical output for SOD depicts horizontal lines corresponding to
parental sequences augmented with bars representing proportional
likelihood of a nucleotide coming from a given sequence and a polyg-
onal line depicting the most likely donor of individual fragments in
the resulting sequence. To achieve this, ClustalW2 is used to align
parental sequences and the sequence being analyzed, each repre-
sented as a horizontal line, with a bar at each position where the
nucleotide on the corresponding donor sequence(s) matches resi-
due(s) in the analyzed sequence. The height of the bar is proportional
to the percentage likelihood that the given residue contributes to the
novel sequence. Gaps between the likelihood bars indicate DNA
stretches not present in the analyzed clone. The contribution line is
calculated as the longest sequence of identity in a 50 to 30 direction.
Implementation was done in Java as a Geneious Plugin. This offers
the opportunity to choose alternative MSAs or performmanual align-
ment adjustments.
Shuffled AAV Capsid Plasmid Library Generation
AAV libraries were generated as previously described14 with
minor modiﬁcations. The capsid genes from WT AAV serotypes
AAV1 (GenBank: NC_002077.1), AAV2 (GenBank: NC_001401.2),
AAV3 (GenBank: AF028705.1), AAV4 (GenBank: NC_001829.1),
AAV5 (ampliﬁed from pXR5 plasmid, which differs at two posi-
tions, G1268C and C2131G, from GenBank: NC_006152.1),
AAV6 (GenBank: AF028704.1), AAV7 (GenBank: AF513851.1),
AAV8 (GenBank: AF513852.1), AAV9 (GenBank: AY530579.1),
AAV10 (GenBank: AY631965.1), AAV11 (GenBank: AY631966.1),
AAV12 (GenBank: DQ813647.1), mAAV-EVE1_modiﬁed (GenBank:80 Molecular Therapy: Methods & Clinical Development Vol. 12 MarchMG657004), and mAAV1 (GenBank: MK026553) were cloned into
the plasmid p-RescueVector (pRV 1–12), a construct based on the
pGEM-T Easy Vector System (catalog [Cat] #A1360; Promega) modi-
ﬁed to harbor trimethoprim resistance and randomized ends ﬂanking
the capsids, for optimal Gibson Assembly (GA). Individual clones
were Sanger sequenced (Garvan Molecular Genetics). Codon-opti-
mized AAV capsid genes were synthesized de novo (Genewiz) and
cloned into the same system (pRV 1–12). Capsid genes (serotypes
1–12, mAAV-EVE1 and mAAV1 for Lib_1-12 and Lib_1-12EM, and
serotypes 2, 5, and 6 for libraries 2/5/6) were excised using SwaI and
NsiI (NEB),mixed at 1:1molar ratios, and digested with 1:10 prediluted
DNaseI (Cat #M030S; NEB) for 2–5 min. The pool of fragments was
separated on a 1% (w/v) agarose gel and fragments ranging from 200
to 1,000 bp (for AAVLib1–12+EM, AAVLib1–12, AAVLiblco1–12+EM,
AAVLiblco1–12) and from 200 to 500 bp (for AAVLib256 and
AAVLiblco256) were recovered using the ZymocleanGel DNARecovery
Kit (Cat #D4001T; Zymogen). For each primer-less PCR reassembly
reaction, 500 ng of gel-extracted fragments was used and
fully reassembled capsids were ampliﬁed in a second PCR with primers
(Shufﬂing_Rescue-F: 50-GTCGGAAAGCATATGCCGCG-30, Shuf-
ﬂing_Rescue-R: 50-GACGTCGCATGCAACTAGTAT-30) binding
the cap gene and carrying overlapping ends to pRV plasmids. A GA
reaction was performed by mixing an equal volume of 2 GAMaster
Mix (Cat #E2611L; NEB) with 1 pmoL PCR-ampliﬁed and
DpnI-treated pRV (BB_GAR-F: 50-ACTTGTTCACTTTGATGGC
GAGG-30, BB_GAR-R: 50-CTGCACACGACATGACATCACG-30)
and 1 pmol of the recovered shufﬂed capsids, at 50C for 30 min.
DNA was ethanol precipitated and electroporated into SS320 electro-
competent E. coli (Cat #60512-2; Lucigen). The total number of trans-
formants was calculated by preparing and plating ﬁve 10-fold serial
dilutions of the electroporated bacteria. The pool of transformants
was grown overnight in 250 mL of Luria-Bertani media supplemented
with trimethoprim (10 mg/mL). Total pRV library plasmids were puri-
ﬁedwith an EndoFreeMaxiprep Kit (Cat #12362; QIAGEN). Thirty in-
dividual clones were picked and Sanger sequenced to sample library
variability. pRV-based libraries were then digested overnight with
SwaI and NsiI, and 1.4 mg of insert was ligated at 16C with T4 DNA
ligase (Cat #M0202;NEB) for 16hr into 1mg of a replication-competent
AAV2-based plasmid platform (p-Replication-Competent [p-RC])
containing ITR-2 and rep2, and unique SwaI and NsiI sites ﬂanking a
1-kb randomized stuffer [ITR2-rep2-(SwaI)-stuffer-(NsiI)-ITR2]. Liga-
tion reactionswere concentrated by using ethanol precipitation, electro-
porated into SS320 electro-competent bacteria, and grown as described
above. Total pRC libraryplasmidswerepuriﬁedwith anEndoFreeMax-
iprep Kit (Cat #12362; QIAGEN).
Production of rAAV Crude Lysates
All rAAV stocks were prepared by polyethylenimine (PEI) (Cat
#239662; Polysciences) triple transfection (2:1 PEI:DNA ratio) of
adherent HEK293T cells (Cat #CRL-3126; ATCC) with pAd5 helper
plasmid,53 AAV transfer vector expressing GFP under the control of
LSP (ssAAV-LSP1-GFP-WPRE-BGHpA),54 and an AAV-helper
plasmid encoding rep2 and the capsid of interest at 2:1:1 molar ratios.
When indicated, pAAP1-12 plasmids expressing FLAG-tagged AAP2019
www.moleculartherapy.orgproteins under the control of the human cytomegalovirus immediate
early (CMV-IE) enhancer-promoter28 were co-transfected to provide
AAP in trans. Cells were seeded 18 hr prior to transfection into 15-cm
tissue culture (TC)-treated dishes to obtain 90% conﬂuency at the
time of transfection. Cells were harvested 72 hr posttransfection
and centrifuged for 20 min at 5,250  g. Media were either discarded
or used for qPCR titration following DNaseI treatment to remove free
plasmid DNA. The cell pellet was resuspended in 1 mL of Benzonase
Buffer (50 mM Tris [pH 8.5] with 2 mM MgCl2) and subjected to
three freeze-thaw cycles. Genomic and free plasmid DNA was
removed by incubating with Benzonase (Merck KGaA, Cat
#1.101695.0002; EMD Chemicals) 200 U/mL at 37C for 1 hr.
Cellular debris was removed by centrifugation for 30 min at
5,250  g. Supernatant was further cleared by adding 1 M CaCl2 to
a ﬁnal concentration of 25 mM and incubated on ice for 1 hr followed
by centrifugation at 5,250 g for 30 min at 4C. Supernatant, 1 mL in
total, was then transferred into a sterile cryotube and stored at80C.
Production of Replication-Competent AAV Libraries
Recombinant AAV capsid libraries were packaged following the same
transfection protocol as described above, with the exception that only
two plasmids were used: the pAd5 helper plasmid and the pRC li-
braries containing ITR-rep2-Caplibrary-ITR at a 1:1 molar ratio. Cell
lysates from ﬁve 15-cm dishes were pooled and puriﬁed using iodix-
anol-based density gradients as previously described.55 Amicon
Ultra-4 Centrifuge Filter Units with Ultracel-100 kDa membrane
(Cat #UFC810024; EMDMillipore) were used to perform a buffer ex-
change (PBS, 50 mM NaCl, 0.001% Pluronic F68 [v/v]; Cat #24040-
032; LifeTech) and concentration step. Based on the efﬁciency of
transformation (total number of individual bacterial colonies), the
variability of the library was estimated to have the upper limit of
2.72  107 variants for AAVLiblco256, 2.4  106 for AAVLib1–12,
3.9  106 for AAVLiblco1–12, 9.8  106 for AAVLib1–12+EM, and
6.9  106 for AAVLiblco1–12+EM.
AAV Titration by Real-Time qPCR
Vector preparations were titrated by real-time qPCR as previously
described56 using the following primers: GFP-F: 50-TCAAGA
TCCGCCACAACATC-30 and GFP-R: 50-TTCTCGTTGGGGTCTT
TGCT-30 for vectors encoding the LSP-GFP cassette, and rep2-F:
50-AAGGATCACGTGGTTGAGGT-30 and rep2-R: 50-CCCACGT
GACGAGAACATTT-30 for replication-competent library prepara-
tions. Serial dilutions of linearized plasmid were used to generate a
standard curve.
Replication-Competent AAV Library Selection in HuH7 Cells
Human hepatomaHuH7 cells weremaintained asmonolayer cultures
in DMEM (Cat #D579; Sigma) supplemented with 10% (v/v) fetal
bovine serum (Cat #F8192; Sigma), 100 mg/mL penicillin, and
100 mg/mL streptomycin. 1  105 cells were seeded per well in two
24-well TC dishes 16 hr prior to infection with AAV library. Four
10-fold dilutions of the AAV library were added to themedia in dupli-
cate plates. Cells were washed with 1 PBS 24 hr after infection and
fresh media added. To facilitate AAV library replication, we addedMoleculWT human Adenovirus 5 (hAd5) (Cat #VR-1516; ATCC) at an
MOI of 0.42 (based on 7-day median TC infective dose [TCID50])
to one of the plates. The plate without hAd5 served as a qPCR control.
Cells were harvested 72 hr after hAd5 infection and lysed by three
freeze-thaw cycles. Cellular debris was removed by centrifugation
and supernatant-containing AAV particles analyzed for AAV ampli-
ﬁcation by qPCR. Eight microliters of the matched library dilutions
(+/ hAd5) was treated with DNaseI (Cat #M030S; NEB) at 37C
for 1 hr, and the enzyme was heat inactivated at 75C for 10 min.
qPCR with rep2-speciﬁc primers was used after each round to
conﬁrm library replication (Figure S2) and to select the library dilu-
tion to be moved into subsequent rounds of selection. At each step
the highest library dilution that resulted in no less than a 2 log in-
crease in AAV signal was selected to minimize cross-packaging of
multiple vectors in single packaging cells and thus increase the strin-
gency of selection. The library dilution selected for subsequent rounds
of ampliﬁcation was incubated at 65C for 30 min to inactivate hAd5,
and iterative selection was performed using the above described
conditions.
Vectorization of Evolved AAV Capsids
After each round of selection, AAV capsid sequences were recovered
from the media by PCR using primers ﬂanking the capsid region
(CapRescue-F: 50-CCCTGCAGACAATGCGAGAGAATGAATCA
GAATTCAAATATCTGC-30, CapRescue-R: 50-ATGCATATGGAA
ACTAGATAAGAAAGAAATACG-30). PCR-ampliﬁed cap genes
were cloned by GA in-frame downstream of the rep2 gene in a recip-
ient pHelper packaging plasmid opened by PCR ampliﬁcation using
the following primers (pHelper-F: 50-CGCATTGTCTGCAGGGAA
ACAGCATC-30, pHelper-R: 50-TTTCTTTCTTATCTAGTTTCCA
TATGCATGTAGATAAGTAGCATGGCGGG-30) and DpnI treated.
Twenty individual clones were sequenced to track progress of the
selection process.
Western Blot Analysis
For western blot analysis of AAV VP and Rep protein, HEK293T cells
were transfected with pAd5 plasmid, pAAV-LSP-GFP plasmid, and
AAV packaging plasmid expressing Rep2 and Cap of corresponding
WT or codon-optimized AAV following the PEI transfection protocol
described above. Cells were harvested 72 hr posttransfection, and total
proteins were extracted using radioimmunoprecipitation assay (RIPA)
buffer (Cat #89900; Pierce, Thermo Fisher, Rockford, IL, USA) supple-
mentedwith protease inhibitors (Cat #04693116001; cOmplete Tablets,
Roche, Mannheim, Germany) and quantiﬁed by Bradford assay. Total
protein (10 mg) was separated by polyacrylamide gel electrophoresis us-
ing 4%–12% NuPAGE BisTris gels (Cat #NP0322; Life Technologies,
Carlsbad, CA, USA) followed by transfer to nitrocellulose membranes
and blocking in PBS/, 5% (w/v) milk powder, and 0.1% (v/v) Tween
20. Detection of VP1+VP2+VP3 proteins was performed using rabbit
polyclonal primary antibody (1:300; Cat #03-61084; American
Research Products, Waltham, MA, USA) and secondary antibody
(goat anti-rabbit IgG-HRP; sc-2004; Santa Cruz Biotechnology, Dallas,
TX, USA) while detection of AAV Rep proteins was performed using
anti-AAV Replicase antibody (mouse monoclonal anti-Rep, 303.9,ar Therapy: Methods & Clinical Development Vol. 12 March 2019 81
Molecular Therapy: Methods & Clinical Development1:100; Cat #03-61069; American Research Products, Waltham, MA,
USA) and secondary antibody (goat anti-mouse IgG-HRP; Cat
#P044701-2; Agilent Dako, Santa Clara, CA, USA). Vinculin (primary
antibody: mouse monoclonal hVIN-1; Cat #V9131; Sigma-Aldrich,
Saint Louis, MO, USA) and matching secondary antibody (goat anti-
mouse IgG-HRP; Cat #P0447; Agilent Dako, Santa Clara, CA, USA)
were used as an endogenous loading control. Signal was detected using
SuperSignal West Pico Chemiluminescent Substrate (Cat #34080;
Thermo Fisher, Rockford, IL, USA) and a FujiFilm Luminescent Image
Analyzer system (LAS-4000).
In Vitro Transduction Analysis
For transduction studies, 2 105 HuH7 cells were plated per well into
24-well TC plates in complete media (DMEM with 10% [v/v] FBS).
Four hours later, the vector stock was diluted into 0.5 mL of complete
media and added to the cells at an indicatedMOI (see ﬁgure legends for
details). Data shown in Figure 4C were generated using the following
MOIs for each vector pair (WT and LCO): AAV1 MOI = 3.2  104,
AAV2 MOI = 2.7  103, AAV3 MOI = 1.0  104, AAV4 MOI =
1.4  104, AAV5 MOI = 5.2  104, AAV6 MOI = 1.6  104, AAV7
MOI = 4.4  105, AAV8 MOI = 2.0  105, AAV9 MOI = 6.3  105,
AAV10 MOI = 3.6  105, AAV11 MOI = 2.8  105, and AAV12
MOI = 4.0 104. The cells were harvested 72 hr after transduction us-
ing TrypLE Express (Cat #12604021; Thermo Fisher) and resuspended
in 200 mL of ﬂuorescence-activated cell sorting (FACS) buffer (PBS/
with 5% [v/v] FBS and 5 mM EDTA). EGFP expression was quantiﬁed
using a BD Fortessa ﬂow cytometer (Westmead Research Hub Flow
Cytometry Facility, Westmead, NSW, Australia), and the data were
analyzed using FlowJo 7.6.1.
Phylogenetic Analysis of Parental AAV Sequences
The 14 parental AAV sequences were aligned using MUSCLE version
3.8.31.57 The phylogenetic relationship among the sequences was in-
ferred by using the maximum likelihood method based on the Ta-
mura-Nei model.58 The tree with the highest log likelihood
(21,217.32) is depicted (Figure 5A). Initial trees for the heuristic
search were obtained automatically by applying Neighbor-Join and
BioNJ algorithms to a matrix of pairwise distances estimated using
the maximum composite likelihood (MCL) approach and then select-
ing the topology with superior log likelihood value. The tree is drawn
to scale, with branch lengths measured in the number of substitutions
per site. There were a total of 2,400 positions in the ﬁnal dataset.
Evolutionary analyses were conducted in MEGA X.59
Statistical Analyses
Statistical analyses were conducted using GraphPad Prism (GraphPad
Software, La Jolla, CA, USA) version 7.0a. Analysis of statistical signif-
icance between two groups in Figures 3B and 3C was performed using
the two-tailed nonparametric Kolmogorov-Smirnov test.
Code Availability
The custom plugin used in this study to perform codon optimization
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